SCHEMBL29630215

SCHEMBL29630215

CCOC(=O)c1c(C)oc2ccc(OCc3cccnc3C(F)(F)F)cc12

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.61
MAPT P10636 5/20 0.60
LMNA P02545 4/20 0.60
ALDH1A1 P00352 4/20 0.57
HIF1A Q16665 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAPK1 P28482 2/20 0.57
L3MBTL1 Q9Y468 5/20 0.55
KDM4E B2RXH2 4/20 0.55
TSHR P16473 3/20 0.55
POLB P06746 2/20 0.55
SLC26A4 O43511 2/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29095725 1.00 PTGS2 (0.61) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL24485216 0.91 MAPT (0.63) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL29095839 0.90 MAPT (0.49) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL29630173 0.90 MAPT (0.49) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL24485031 0.89 SLC26A4 (0.69) PTGS2MAPTLMNAL3MBTL1TSHR
SCHEMBL29095787 0.89 MAPT (0.48) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL29630234 0.89 MAPT (0.48) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL29630233 0.88 MAPT (0.49) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL29095836 0.88 MAPT (0.49) PTGS2MAPTLMNAALDH1A1HIF1A
SCHEMBL24485030 0.87 PTGS2 (0.66) PTGS2MAPTLMNAALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 PTGS2 283/4885MAPT 2911/4885LMNA 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.